igrelimogene litadenorepvec

AXP000009.2 · Oncolytic virus

Platform
adenovirus (Ad5/3 chimera, E2F promoter, Delta-24)
Originator
TILT Biotherapeutics
Sponsor
TILT Biotherapeutics

Names

NameTypeSource
igrelimogene litadenorepvecpreferred name, INNcurator, ncit
Ad5/3-E2F-d24-hTNFa-IRES-hIL2codencit
TILT-123codencit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5/3 chimera
Replication
conditionally replicating
Modifications
E2F promoter drives E1A; 24-bp E1A CR2 deletion; Ad3 fiber knob
Transgenes
TNF, IL2
Route
intratumoral, intravenous, intraperitoneal
Source
evidence

Cross-references

NCI Thesaurus
C175454
FDA UNII
484TEV85XS

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06961786TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of MelanomaActive not recruitingPhase 12025-06-252026-119Metastatic Melanoma
NCT06125197Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung CancerActive not recruitingPhase 12024-07-232026-01-3022Lung Cancer
NCT05222932Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active not recruitingPhase 12023-03-082026-1215Head and Neck Squamous Cell Carcinoma; Melanoma
NCT05271318Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active not recruitingPhase 1/22022-05-172027-0329Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin; Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin; Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin; Platinum-refractory Ovarian Carcinoma; Platinum-resistant Ovarian Cancer
NCT04695327TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 MonotherapyCompletedPhase 12021-01-112025-09-0332Solid Tumor
NCT04217473TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced MelanomaCompletedPhase 12020-02-262023-12-1217Metastatic Melanoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41566775Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy2026cited by trial NCT04217473
PMID 42136030Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy2026name in title: TILT-123
PMID 42624531Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.Journal for immunotherapy of cancer2026cited by trial NCT04217473
PMID 39870491Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.Journal for immunotherapy of cancer2025name in abstract: igrelimogene litadenorepvec
PMID 39910037The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.Nature communications2025name in title: TILT-123
PMID 40107242Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.Cell reports. Medicine2025name in title: TILT-123
PMID 40211048Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.Cancer gene therapy2025name in title: TILT-123
PMID 38546220Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research2024name in title: TILT-123
PMID 39506856Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.Journal of experimental & clinical cancer research : CR2024cited by trial NCT04217473
PMID 33513935Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.Cells2021cited by trial NCT04217473
PMID 32322662Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.Molecular therapy oncolytics2020cited by trial NCT04217473

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41957950Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.Oncoimmunology2026name in abstract: igrelimogene litadenorepvec
PMID 42970481Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses.International journal of cancer2026name in abstract: igrelimogene litadenorepvec
PMID 42982510Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy.Journal for immunotherapy of cancer2026name in title: TILT-123
PMID 41029444Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.Experimental hematology & oncology2025name in abstract: TILT-123
PMID 39801682Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.Immuno-oncology technology2024name in title: TILT-123
PMID 36817448Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.Frontiers in immunology2023name in abstract: TILT-123
PMID 37546696Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.Oncoimmunology2023name in abstract: TILT-123
PMID 35997357Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.Diseases (Basel, Switzerland)2022name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2
PMID 33922052Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.Cells2021name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2
PMID 31940588Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.Journal for immunotherapy of cancer2020name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2
PMID 32225009TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.Cells2020name in abstract: TILT-123
PMID 32923123Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.Oncoimmunology2020name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2
PMID 29721366TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.Oncoimmunology2018name in abstract: TILT-123
PMID 30017877Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.Molecular therapy : the journal of the American Society of Gene Therapy2018name in abstract: TILT-123
PMID 30569015Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.Molecular therapy oncolytics2018name in abstract: TILT-123
PMID 28345026Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.Molecular therapy oncolytics2017name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2

Notes

Construct name Ad5/3-E2F-d24-hTNFa-IRES-hIL2 from NCIt; transgenes TNF-alpha and IL-2. Transgenes moved from targets to virus.tsv (spec 0.2).

How to cite

igrelimogene litadenorepvec (AXP000009.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000009.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.